Skip to main content
TipRanks
Go Ultimate75% OFF

Revolution Medicines (42Z) Stock Statistics & Valuation Metrics

17 Followers

Total Valuation

Revolution Medicines has a market cap or net worth of EUR 31.51B. The enterprise value is EUR 41.68B.

Market Cap
EUR 31.51B
Enterprise Value
EUR 41.68B

Share Statistics

Revolution Medicines has 216,292,330 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
216,292,330
Owned by Insiders
2.04%
Owned by Institutions
90.42%

Financial Efficiency

Revolution Medicines’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -56.83%.

Return on Equity (ROE)
-0.69
Return on Assets (ROA)
-0.48
Return on Invested Capital (ROIC)
-56.83%
Return on Capital Employed (ROCE)
-0.57
Revenue Per Employee
0
Profits Per Employee
-1.28M
Employee Count
883
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Revolution Medicines is -17.47. Revolution Medicines’s PEG ratio is 0.35.

PE Ratio
-17.47
PS Ratio
174.97
PB Ratio
14.30
Price to FCF
-23.99
Price to Operating Cash Flow
-24.00
PEG Ratio
0.35

Income Statement

In the last 12 months, Revolution Medicines had revenue of 0 and earned -1.13B in profits. Earnings per share was -5.95.

Revenue
0
Gross Profit
-16.56M
Operating Income
-1.18B
Pretax Income
-1.13B
Net Income
-1.13B
EBITDA
-1.09B
Earnings Per Share (EPS)
-5.95

Cash Flow

In the last 12 months, operating cash flow was -1.43B and capital expenditures -9.45M, giving a free cash flow of -1.44B billion.

Operating Cash Flow
-1.43B
Free Cash Flow
-1.44B
Free Cash Flow per Share
-6.70

Dividends & Yields

Revolution Medicines pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-4.17%
Earnings Yield
-5.45%

Stock Price Statistics

Beta
0.80
52-Week Price Change
145.80%
50-Day Moving Average
171.76
200-Day Moving Average
140.63
Relative Strength Index (RSI)
30.78
Average Volume (3m)
283

Important Dates

Revolution Medicines upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 04, 2026
Next Earnings Date
Mar 01, 2027
Ex-Dividend Date
―

Financial Position

Revolution Medicines as a current ratio of 7.14, with Debt / Equity ratio of 9.73%

Current Ratio
7.14
Quick Ratio
7.14
Debt to Market Cap
0.01
Net Debt to EBITDA
0.21
Interest Coverage Ratio
-48.80

Taxes

In the past 12 months, Revolution Medicines has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Revolution Medicines EV to EBITDA ratio is -19.49, with an EV/FCF ratio of -24.01.

EV to Sales
175.09
EV to EBITDA
-19.49
EV to Free Cash Flow
-24.01
EV to Operating Cash Flow
-24.17

Balance Sheet

Revolution Medicines has EUR 3.65B in cash and marketable securities with EUR 639.10M in debt, giving a net cash position of EUR 3.01B billion.

Cash & Marketable Securities
EUR 3.65B
Total Debt
EUR 639.10M
Net Cash
EUR 3.01B
Net Cash Per Share
EUR 13.93
Tangible Book Value Per Share
EUR 10.85

Margins

Gross margin is 95.16%, with operating margin of -852.98%, and net profit margin of -946.82%.

Gross Margin
95.16%
Operating Margin
-852.98%
Pretax Margin
-948.02%
Net Profit Margin
-946.82%
EBITDA Margin
-898.20%
EBIT Margin
-906.65%

Analyst Forecast

The average price target for Revolution Medicines is EUR 245.62, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
EUR 245.62
Price Target Upside
67.94% Upside
Analyst Consensus
Strong Buy
Analyst Count
24
Revenue Growth Forecast
―
EPS Growth Forecast
-67.73%

Scores

Smart Score
6
AI Score
―